Evaluating the Current Literature on Treatments Containing Adipose-Derived Stem Cells for Osteoarthritis: a Progress Update

Ranmuthu, Chanuka D. S.; Ranmuthu, Charindu K. I.; Khan, Wasim

doi:10.1007/s11926-018-0776-7

Cited by 13 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…Generally, there are two ways of delivering AD-MSCs: i) cultured AD-MSCs, and ii) in stromal vascular fraction (SVF) [15] . SVF from adipose tissue showed a mixed cell population of polygonal and fibroblastic cells, some containing a small proportion of MSCs and lipid droplets in their cytoplasm, whereas AD-MSCs displayed a spindle-shaped morphology and a very specific homogenous stem cells population [4,15] . While the current literature focused more on the use of AD-MSCs in patients with knee OA and showed satisfactory clinical and functional improvement, pain relief and structural regeneration of articular cartilage [2,9,11] ; clinical studies on SVF [4,8] demonstrated its chondroprotective, immunomodulatory, anti-fibrotic and anti-inflammatory properties [6] , suggesting a safe therapeutic approach for the treatment of severe knee OA.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of AD-MSCs injections for the treatment of knee osteoarthritis: Analysis of the current literature

Vasiliadis

Galanis

2020

JSRM

View full text Add to dashboard Cite

Introduction: Knee osteoarthritis (OA) is a common pathology and is one of the leading causes of chronic disability among people aged over 65 years old. Currently, cell-based therapies involving intra-articular delivery of MSCs have emerged as a potential treatment solution.Objective: The purpose was to examine the current literature regarding the clinical application of adipose-derived mesenchymal stem cells (AD-MSCs) for the management of knee OA. Materials and methods:The electronic database, PubMed was searched from inception to May 31, 2019. This review included studies using cell population containing AD-MSCs for the treatment of knee OA. Data on clinical outcomes measured by various instrument such as VAS, WOMAC, KSS, KOOS, SF-36 were analysed, while MRI provided reliable and quantitative data on cartilage status throughout most compartments of the knee.Results: A total of eight studies were included. Six studies used cultured AD-MSCs, while two studies used stromal vascular fraction. There were no significant adverse events related to the procedure, while the most of studies reported improvement from baseline in at least one outcome measure. The findings were not necessarily reflected in MRI evaluations nor were improvements always maintained after 2 years follow-up. Conclusion:Our data suggest that the intra-articular injection of autologous AD-MSCs is a safe and effective therapeutic alternative for the treatment of severe knee OA patients and may have the potential to attenuate progression of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Effectiveness of AD-MSCs injections for the treatment of knee osteoarthritis: Analysis of the current literature

Vasiliadis

Galanis

2020

JSRM

View full text Add to dashboard Cite

show abstract

“…used adipose-derived MSCs to treat OA and they found that the treatment group had slight discomforts and bruises after the fat extraction [ 57 ]. Ranmuthu et al also reported adverse events such as local pain and swelling at the fat collection site [ 58 ]. Studies from Draganski et al proved that even if professionally trained personnel performs bone marrow harvesting, there are risks of discomfort, postoperative pain, and infection during the harvesting process, while allogeneic sources may lead to risks such as disease transmission and graft-versus-host disease [ 59 ].…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal stem cell-derived extracellular vesicles prevent the development of osteoarthritis via the circHIPK3/miR-124-3p/MYH9 axis

Liu

et al. 2021

J Nanobiotechnol

View full text Add to dashboard Cite

Background Extracellular vesicles (EVs) secreted by mesenchymal stem cells (MSCs) may play a vital role in a variety of biological processes, including cartilage regeneration. However, few studies reported their potential in the development of osteoarthritis (OA) previously. In this study, we explored the biological roles and underlying mechanism of MSCs-EVs in OA. Results Co-culture experiments revealed that MSCs-EVs could promote the expression of collagen type II alpha 1 chain (COL2A1), SRY-box transcription factor 9 (SOX9) and Aggrecan while negatively regulate the expression of chondrocyte hypertrophy markers matrix metallopeptidase 13 (MMP-13) and RUNX family transcription factor 2 (Runx2) in mouse chondrocytes in the OA model. Besides, the results of cell experiments indicated that MSCs-EVs could notably weaken the suppression of chondrocyte proliferation, migration and the promotion of chondrocyte apoptosis via interleukin1β (IL-1β) induction. In addition, MSCs-circHIPK3-EVs (EVs derived from MSCs overexpressing circHIPK3) considerably improved IL-1β-induced chondrocyte injury. Mechanistically, we elucidated that circHIPK3 could directly bind to miR-124-3p and subsequently elevate the expression of the target gene MYH9. Conclusion The findings in our study demonstrated that EVs-circHIPK3 participated in MSCs-EVs-mediated chondrocyte proliferation and migration induction and in chondrocyte apoptosis inhibition via the miR-124-3p/MYH9 axis. This offers a promising novel cell-free therapy for treating OA. Graphic abstract

show abstract

“…In May 2021, we conducted a search in seven electronic databases: MEDLINE via PubMed, Epistemonikos, PEDro, DynaMed, TripDatabase, Elsevier via Clinicalkey and Cochrane Controlled Trials Register. In addition, we manually searched references from all available reviews 15 , 20 – 29 on SVF to verify that none were missing from our initial search. The search included the terms ‘stromal vascular fraction’, ‘knee osteoarthritis’ or ‘osteoarthritis’, ‘cartilage’, ‘adipose-derived stem cells’ or ‘adipose-derived stromal cells’, and ‘mesenchymal stem cells’ or ‘mesenchymal stromal cells’ in the title and abstract of all trial registers and databases.…”

Section: Methodsmentioning

confidence: 99%

Stromal vascular fraction therapy for knee osteoarthritis: a systematic review

Boada-Pladellorens

Avellanet

Pagés-Bolibar

et al. 2022

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Background: Regenerative cell therapies, such as adipose-derived stromal vascular fraction (SVF), have been postulated as potential treatments for knee osteoarthritis (KOA). Objectives: To assess the efficacy and safety of SVF treatment against placebo and other standard therapies for treating KOA in adult patients. Design: A systematic review. Data sources and methods: We searched the following databases: MEDLINE via PubMed, Epistemonikos, PEDro, DynaMed, TripDatabase, Elsevier via Clinicalkey and Cochrane Controlled Trials Register. We included prospective interventional studies where treatment with SVF in adults with KOA was compared against placebo or other standard therapies, and results were objectively measured with at least one widely recognised osteoarthritis scale. Results: Among 266 studies published until May 2021, nine met our inclusion criteria. A total of 239 patients (274 knees) were included in our study. The follow-up ranged from 6 to 24 months. Six studies had a control group (only one being placebo). All studies showed that SVF improved pain and functionality measured, in most cases, with the visual analogue scale and the Western Ontario and McMaster Universities Osteoarthritis Index. In addition, five studies reported an improvement in anatomical structures, as detected in MR images. However, the number of cells contained in SVF varied substantially between different studies, which could induce a comparison bias. Conclusion: Although based on a small number of dissimilar studies, SVF was considered a safe treatment for KOA and could be promising in terms of pain, functionality and anatomical structure improvement. However, SVF products need to be standardised, the number of cells homogenised and the use of concomitant treatments reduced to establish proper comparisons. Registration: PROSPERO registration number: CRD42021284187.

show abstract

Evaluating the Current Literature on Treatments Containing Adipose-Derived Stem Cells for Osteoarthritis: a Progress Update

Cited by 13 publications

References 31 publications

Effectiveness of AD-MSCs injections for the treatment of knee osteoarthritis: Analysis of the current literature

Effectiveness of AD-MSCs injections for the treatment of knee osteoarthritis: Analysis of the current literature

Mesenchymal stem cell-derived extracellular vesicles prevent the development of osteoarthritis via the circHIPK3/miR-124-3p/MYH9 axis

Stromal vascular fraction therapy for knee osteoarthritis: a systematic review

Contact Info

Product

Resources

About